Research progress of population pharmacokinetics applying to individualized medication

LIN Yan

doi:10.3969/j.issn.1006-0111.2015.04.002

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 33 Issue 4

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2015 > 33(4): 293-297,346

LIN Yan. Research progress of population pharmacokinetics applying to individualized medication[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002

Citation:

LIN Yan. Research progress of population pharmacokinetics applying to individualized medication[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002

Research progress of population pharmacokinetics applying to individualized medication

doi: 10.3969/j.issn.1006-0111.2015.04.002

LIN Yan

Department of Pharmacy, Yangpu Hospital affiliated to Tongji University, Shanghai 200433, China

Received Date: 2014-07-18
Rev Recd Date: 2015-03-14

Abstract

Combining the classic pharmacokinetic principles and statistical methods, population pharmacokinetics (PPK) can predict individual pharmacokinetic parameters accurately with sparse data in patients, which may be used for monitoring drug concentration in patients and realizing individual dose regimen. In this article, we review the recent application of PPK in drugs with narrow therapeutic windows or great individual differences, combining medication, medication in special populations and so on, providing useful information for further investigation of PPK and its application in clinical medication.
- population pharmacokinetics,
- individual dose regimen,
- nonlinear mixed effect model,
- Bayesian forecasting

References

[1]	倪天庆, 胡思源, 司端运, 等. 中药儿童群体药动学试验设计要点[J]. 中草药, 2013, 44(021): 3089-3091.
[2]	张弨, 翟所迪. 群体药动学在治序药物监测中的应用[J]. 临床药物治疗杂志, 2006, 4(1): 45-50.
[3]	蒋新国.生物药剂学与药物动力学[M]. 北京: 高等教育出版社, 2009: 538-540.
[4]	Tatarinova T, Neely M, Bartroff J, et al.Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian[J].J Pharmacokinet Pharmacodyn, 2013, 40(2): 189-199.
[5]	Wakefield J, Walker S. Bayesian nonparametric population models: formulation and comparison with likelihood approaches[J].J Pharmacokinet Biopharm, 1997, 25(2): 235-253.
[6]	Rosner GL, Muller P. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models[J].J Pharmacokinet Biopharm, 1997, 25(2): 209-233.
[7]	林翠鸿, 王长连, 柯蒙. 群体药动学及其在个体化给药中的应用[J].中国临床药学杂志, 2005,14(01): 58-60.
[8]	Schaeftlein A, Minichmayr IK, Kloft C. Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data[J].Eur J Pharm Sci, 2014,57:68-73.
[9]	Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy[J].Ther Drug Monit, 2012, 34(4): 368-371.
[10]	胡敏, 张静华, 孙鹤, 等. 群体药动学原理及NONMEM法数据分析[J].药学服务与研究, 2002,2(4): 227-230.
[11]	Sherwin CM, Kiang TK, Spigarelli MG, et al. Fundamentals of population pharmacokinetic modelling: validation methods[J].Clin Pharmacokinet, 2012, 51(9): 573-590.
[12]	Krauss M, Burghaus R, Lippert JOR, et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification[J].In Silico Pharmacology, 2013, 1(1): 1-11.
[13]	Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J].Clin Pharmacokinet, 2004, 43(10): 623-653.
[14]	Golubovic B, Vucicevic K, Radivojevic D, et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients—population pharmacokinetic approach[J].Eur J Pharm Sci, 2013, 52: 34-40.
[15]	Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients[J].J Clin Pharmacol, 2014, 54(2):215-224.
[16]	Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type[J].J Clin Pharm Ther, 2009, 34(4): 473-483.
[17]	翁芳娟. 万古霉素的群体药动学研究[J].海峡药学, 2013,25(7): 207-209.
[18]	N PP, D BBF. The epilepsy prescriber's guide to antiepileptic drugs[M].Oxford: Cambridge University Press, 2010.
[19]	Jovanovic M, Sokic D, Grabnar I, et al. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling[J].Eur J Pharm Sci, 2013, 50(3-4): 282-289.
[20]	Marsot A, Boulamery A, Bruguerolle B, et al. Population pharmacokinetic analysis during the first 2 years of life: an overview[J].Clin Pharmacokinet, 2012, 51(12): 787-798.
[21]	Udy AA, Covajes C, Taccone FS, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?[J].Int J Antimicrob Agents, 2013, 41(6): 564-568.
[22]	Conil JM, Georges B, Fourcade O, et al. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration[J].Int J Clin Pharmacol Ther, 2007, 45(3): 133-142.
[23]	Conil JM, Georges B, Ravat F, et al. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations[J].Clin Ther, 2013, 35(10): 1603-1612.
[24]	柳晓泉, 陈渊成, 郝琨, 等. 药动学一药效学结合模型的研究进展及在新药研发中的应用[J].中国药科大学学报, 2007, 38(6): 481-488.
[25]	王清, 朱萱萱, 周杰, 等. 参麦注射液在心肌缺血患者体内的群体药动学研究[J].中华中医药学刊, 2013,31(12): 2702-2705.
[26]	Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the neoral formulation[J].Biodrugs, 2001, 15(5): 279-290.
[27]	Yoshida K, Kimura T, Hamada Y, et al. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from sandimmune to neoral in stable renal transplant patients[J].Transplant P, 2001, 33(7): 3146-3147.
[28]	Yue CS, Huynh HH, Raymond C, et al. Population pharmacokinetic and pharmacodynamic modeling of acetazolamide in peritoneal dialysis patients and healthy volunteers[J].J Pharm Pharm Sci, 2013, 16(1): 89-98.
[29]	Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil[J].J Clin Pharmacol, 2013, 53(1): 29-40.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(5084) PDF downloads(871) Cited by()

Proportional views

Research progress of population pharmacokinetics applying to individualized medication

Department of Pharmacy, Yangpu Hospital affiliated to Tongji University, Shanghai 200433, China

Received Date: 2014-07-18

Rev Recd Date: 2015-03-14

Key words:

Abstract: Combining the classic pharmacokinetic principles and statistical methods, population pharmacokinetics (PPK) can predict individual pharmacokinetic parameters accurately with sparse data in patients, which may be used for monitoring drug concentration in patients and realizing individual dose regimen. In this article, we review the recent application of PPK in drugs with narrow therapeutic windows or great individual differences, combining medication, medication in special populations and so on, providing useful information for further investigation of PPK and its application in clinical medication.

HTML

Reference (29)

[1]	倪天庆, 胡思源, 司端运, 等. 中药儿童群体药动学试验设计要点[J]. 中草药, 2013, 44(021): 3089-3091.
[2]	张弨, 翟所迪. 群体药动学在治序药物监测中的应用[J]. 临床药物治疗杂志, 2006, 4(1): 45-50.
[3]	蒋新国.生物药剂学与药物动力学[M]. 北京: 高等教育出版社, 2009: 538-540.
[4]	Tatarinova T, Neely M, Bartroff J, et al.Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian[J].J Pharmacokinet Pharmacodyn, 2013, 40(2): 189-199.
[5]	Wakefield J, Walker S. Bayesian nonparametric population models: formulation and comparison with likelihood approaches[J].J Pharmacokinet Biopharm, 1997, 25(2): 235-253.
[6]	Rosner GL, Muller P. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models[J].J Pharmacokinet Biopharm, 1997, 25(2): 209-233.
[7]	林翠鸿, 王长连, 柯蒙. 群体药动学及其在个体化给药中的应用[J].中国临床药学杂志, 2005,14(01): 58-60.
[8]	Schaeftlein A, Minichmayr IK, Kloft C. Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data[J].Eur J Pharm Sci, 2014,57:68-73.
[9]	Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy[J].Ther Drug Monit, 2012, 34(4): 368-371.
[10]	胡敏, 张静华, 孙鹤, 等. 群体药动学原理及NONMEM法数据分析[J].药学服务与研究, 2002,2(4): 227-230.
[11]	Sherwin CM, Kiang TK, Spigarelli MG, et al. Fundamentals of population pharmacokinetic modelling: validation methods[J].Clin Pharmacokinet, 2012, 51(9): 573-590.
[12]	Krauss M, Burghaus R, Lippert JOR, et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification[J].In Silico Pharmacology, 2013, 1(1): 1-11.
[13]	Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J].Clin Pharmacokinet, 2004, 43(10): 623-653.
[14]	Golubovic B, Vucicevic K, Radivojevic D, et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients—population pharmacokinetic approach[J].Eur J Pharm Sci, 2013, 52: 34-40.
[15]	Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients[J].J Clin Pharmacol, 2014, 54(2):215-224.
[16]	Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type[J].J Clin Pharm Ther, 2009, 34(4): 473-483.
[17]	翁芳娟. 万古霉素的群体药动学研究[J].海峡药学, 2013,25(7): 207-209.
[18]	N PP, D BBF. The epilepsy prescriber's guide to antiepileptic drugs[M].Oxford: Cambridge University Press, 2010.
[19]	Jovanovic M, Sokic D, Grabnar I, et al. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling[J].Eur J Pharm Sci, 2013, 50(3-4): 282-289.
[20]	Marsot A, Boulamery A, Bruguerolle B, et al. Population pharmacokinetic analysis during the first 2 years of life: an overview[J].Clin Pharmacokinet, 2012, 51(12): 787-798.
[21]	Udy AA, Covajes C, Taccone FS, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?[J].Int J Antimicrob Agents, 2013, 41(6): 564-568.
[22]	Conil JM, Georges B, Fourcade O, et al. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration[J].Int J Clin Pharmacol Ther, 2007, 45(3): 133-142.
[23]	Conil JM, Georges B, Ravat F, et al. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations[J].Clin Ther, 2013, 35(10): 1603-1612.
[24]	柳晓泉, 陈渊成, 郝琨, 等. 药动学一药效学结合模型的研究进展及在新药研发中的应用[J].中国药科大学学报, 2007, 38(6): 481-488.
[25]	王清, 朱萱萱, 周杰, 等. 参麦注射液在心肌缺血患者体内的群体药动学研究[J].中华中医药学刊, 2013,31(12): 2702-2705.
[26]	Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the neoral formulation[J].Biodrugs, 2001, 15(5): 279-290.
[27]	Yoshida K, Kimura T, Hamada Y, et al. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from sandimmune to neoral in stable renal transplant patients[J].Transplant P, 2001, 33(7): 3146-3147.
[28]	Yue CS, Huynh HH, Raymond C, et al. Population pharmacokinetic and pharmacodynamic modeling of acetazolamide in peritoneal dialysis patients and healthy volunteers[J].J Pharm Pharm Sci, 2013, 16(1): 89-98.
[29]	Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil[J].J Clin Pharmacol, 2013, 53(1): 29-40.

Message Board

Research progress of population pharmacokinetics applying to individualized medication

doi: 10.3969/j.issn.1006-0111.2015.04.002

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views